Many countries have observed an increase in the incidence of invasive fungal infections (IFIs) over the past two decades with emergence of new risk factors and isolation of new fungal pathogens. Early diagnosis and appropriate antifungal treatment remain the cornerstones of successful outcomes. However, due to non-specific clinical presentations and limited availability of rapid diagnostic tests, in more than half of cases antifungal treatment is inappropriate. As a result, the emergence of antifungal resistance both in yeasts and mycelial fungi is becoming increasingly common. The Delhi Chapter of the Indian Association of Medical Microbiologists (IAMM-DC) organized a 1 day workshop in collaboration with BSAC on 10 December 2015 in New Delhi to design a road map towards the development of a robust antifungal stewardship programme in the context of conditions in India. The workshop aimed at developing a road map for optimizing better outcomes in patients with IFIs while minimizing unintended consequences of antifungal use, ultimately leading to reduced healthcare costs and prevention development of resistance to antifungals. The workshop was a conclave of all stakeholders, eminent experts from India and the UK, including clinical microbiologists, critical care specialists and infectious disease physicians. Various issues in managing IFIs were discussed, including epidemiology, diagnostic and therapeutic algorithms in different healthcare settings. At the end of the deliberations, a consensus opinion and key messages were formulated, outlining a step-by-step approach to tackling the growing incidence of IFIs and antifungal resistance, particularly in the Indian scenario.
Introduction
Invasive fungal infections (IFIs) are increasingly recognized as a significant health problem worldwide, especially among immunocompromised patients. The incidence of IFI increased by 1.5% per year and that of deaths by 2.9% per year over a period of 10 years, between 2001 and 2010, in France. Furthermore, the incidence of candidaemia, invasive aspergillosis (IA) and mucormycosis increased there by 7.8%, 4.4% and 7.3% per year, respectively. 1 In spite of the availability of new and effective antifungal agents, IFI still carries a 45%-63% mortality rate for IA 2, 3 and an 47% mortality rate for invasive candidiasis. 4 Early diagnosis and treatment remain the cornerstones of better prognosis. Unfortunately, early diagnosis of fungal infections is a challenge due to non-specific clinical manifestations and the low sensitivity and specificity of microbiology cultures and radiology, respectively, which are the most common diagnostic techniques used. 5 For better understanding of this article by our readers it is necessary to provide a brief description of the current Indian healthcare system. Most of the healthcare requirements of patients are met out of pocket by them, even though predominantly healthcare V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com facilities in India are state run. Corporations and other private trust bodies running hospitals have grown over a period of time but are prohibitively expensive. The concept of health insurance is not universal and most of the population cannot afford to have health cover. As a result, the healthcare expenditures are by and large borne by patients themselves out of their meagre lifetime savings.
Indian medical societies' initiative for antifungal stewardship
The Indian healthcare system does not have a nationwide surveillance programme for invasive fungal disease. The Indian subcontinent has an increasing population of diabetics and the lifespan of individuals on average has also gone up. Surgical procedures and high-risk surgeries such as coronary artery bypass grafting (CABG), joint replacements and organ transplants are everyday events across the country. In the light of this, the time has come for a nationwide surveillance programme and a fungal registry.
Over several years, the Indian Association of Medical Microbiologists (IAMM) has addressed various aspects of the development of antibiotic resistance and published a commentary and editorials to create awareness in the Indian subcontinent through their journal, the Indian Journal of Medical Microbiology. 6 Since 2010, academia in India, with the help of the Ministry of Health and Family Welfare of the Government of India, has launched several antimicrobial stewardship programmes. [7] [8] [9] The Indian Council of Medical Research (ICMR) created five nodal centres for monitoring antibacterial resistance. Various research centres across the country are also being created to analyse broad-based data on bacterial resistance and prevalence in India. One of the centres at Chandigarh has also been made the nodal centre for documentation of fungal infections across India.
The Delhi Chapter of IAMM has taken an initiative in antimicrobial stewardship. In 2014, collaboration with the BSAC was established through a memorandum of understanding (MOU) with a common goal of 'training the trainers' in the area of antimicrobial stewardship programmes (AMSPs). The understanding was to bring about behavioural changes among prescribers by spreading knowledge and awareness in the field of AMSPs. The first year of association with BSAC was dedicated to AMSPs and more stakeholders, including the Public Health Foundation of India (PHFI) and the Indian Association of Physicians (IAP), joined the endeavour. However, relatively little attention is being paid to antifungal resistance and the possibility of an antifungal stewardship programme. In 2015, collaboration with the BSAC was established with a common goal of developing a roadmap for an antifungal stewardship programme in India. The participants attending the workshop felt that addressing issues in antifungal stewardship was imperative to address the growing threat of antifungal resistance.
A full-day programme was held on Friday 11 December 2015 in New Delhi, India, where the extent of antifungal resistance and antimicrobial stewardship were discussed in detail. A workshop was organized, which was attended by 100 invited delegates and 13 faculty members drawn from clinical microbiology, critical care, infectious diseases, surgery and haemato-oncology.
The outline of the workshop is described below.
Definition of antifungal stewardship programme
Optimal use of antifungals through careful selection of agents based on patient profile, target organism, toxicity, cost and the likelihood of emergence and spread of antifungal resistance.
Threats identified • The high cost and toxicity of antifungals and several challenging issues in management of fungal diseases justify separate emphasis on an antifungal stewardship programme.
• The emergence of antifungal resistance is a matter of concern, particularly as there is very limited development of new antifungals.
• Local epidemiology with continuous surveillance is of crucial importance for developing management guidelines and deciding on the choice of antifungal agent.
• Experts should develop the guideline and it should be available at the point of care for all clinicians.
• Withdrawal or de-escalation of antifungals, especially during empirical therapy, should receive special attention.
• Daily coordination between clinicians, including specialists in infectious diseases and microbiologists (mycologists), is essential to manage fungal infections of individual patients.
• Biomarker/molecular tests (galactomannan, b-D-glucan, Candida spp. and Aspergillus spp. PCR) and CT imaging should be available at all tertiary care centres in India.
• Therapeutic drug monitoring of azole antifungals, particularly voriconazole, posaconazole and itraconazole, is desirable.
• Regular auditing of the total amount of antifungal use, as well as toxicity and healthcare costs is important. (10%-15%) and certain filamentous fungi 11 (5%-15%), e.g. acquired resistance of Aspergillus fumigatus and constitutive resistance of Scedosporium apiospermum.
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Objectives Primary
To optimize better outcomes for patients with IFIs while minimizing any unintended consequences of antifungal use, including toxicity, selection of resistant fungi and emergence of antifungal resistance.
Secondary
To reduce healthcare costs. 
Results of the deliberations
The reported incidence of candidaemia ranges from 1.2 to 26/ 100 000 inhabitants 13, 14 and most cases are healthcare associated. The Indian subcontinent is encountering more Candida yeast infections, with the predominant species being Candida tropicalis, Candida parapsilosis and Candida glabrata as well as Candida albicans. In a recent prospective nationwide, multicentre, observational study conducted at 27 ICUs across India, Chakrabarti et al. 10 reported a high incidence of candidaemia (6.51 cases/1000 ICU admissions), acquisition occurring early after admission to the ICU (median 8 days; IQR 4-15 days). A vast spectrum of organisms (31 Candida spp.) was isolated, with a preponderance of C. tropicalis. Azole and multidrug resistance was seen in 11.8% and 1.9% of isolates, respectively.
The overall susceptibility of Candida spp. to all antifungals remains high but is changing; Oberoi et al. 15 observed an overall 5-fold increase in cases of candidaemia over a 10 year period (1999-2008) in a tertiary care hospital at New Delhi, with a significant increase in the ICU. The isolation of Candida spp. other than C. albicans also significantly increased during this period. Between 2006 and 2008, C. tropicalis (29.2%) was the most common isolate, followed by C. albicans (16.8%), Candida haemulonii (15.5%), C. parapsilosis (12.5%) and C. glabrata (8.5%). Increasing isolation of C. haemulonii showing higher MICs of amphotericin B and resistance to fluconazole was also observed during the same period. Reduced susceptibility to fluconazole was seen for C. glabrata (60.8%), C. parapsilosis (66.1%) and C. tropicalis (90.5%). Between 2008 and 2011, at the same centre, Wattal et al. 16 found that Candida species were the second most common isolates from blood cultures causing infection in the ICU. C. tropicalis (19.7%) was the most common isolate, followed by C. haemulonii (17.9%) and C. parapsilosis (16.5%). C. glabrata (25.8%) and C. parapsilosis (37.4%) showed increasing resistance to fluconazole using the automated VITEK 2 (bioMérieux, France). From 2013 onwards it became clear that isolates of C. haemulonii were misidentified by the automated VITEK-2 system (bioMérieux, France) and found to be Candida auris when molecular identification techniques were employed. An MDR endemic clonal strain of C. auris was identified by other workers as well. 17 Invasive mould infections present another major challenge in managing critically ill patients in hospitals, with IA being the second most common IFI. [18] [19] [20] The incidence of invasive mucormycosis is also increasing, especially in India among patients with uncontrolled diabetes. 21 Autopsy data from a tertiary care centre in north India found evidence of IFI in 2.4% (365/15 040) of all autopsies, with invasive aspergillosis (42%) and mucormycosis (23%) predominating (Ashim Das, PGIMER, Chandigarh, India, personal communication). In one stem cell transplant unit at a centre in south India, the rate of IFI was 19.7%, with 70% of cases due to IA and 8% due to mucormycosis. 22 The high rate was thought to be related to high spore counts resulting from construction activity in the vicinity and fungal contamination of the air-conditioning ducting systems. Most developing nations, including India, are under constant construction. As a result, construction activity in and around hospitals or healthcare facilities is a common sight. Even though many hospitals have hospital infection control practices in place, air-handling machinery is usually either absent or lags behind in providing adequate air changes. Environmental sampling, particularly air sampling of high-risk areas such as operation theatres, is not universally followed. Moreover, there is no Indian reference for a significant air colony count for moulds Review JAC available in the country based on objective data. Since much more basic infrastructure is still lacking in the country, addressing various issues in fungal stewardship, such as MIC testing or the concept of therapeutic dose monitoring (TDM), is currently difficult to recommend on a routine basis, though this needs to be aimed at in the interests of patient care.
Owing to the low sensitivity of conventional diagnosis and the limited availability of biomarker tests in Indian laboratories, the majority of patients are treated empirically with antifungals without any diagnosis-driven approach, which leads to the overuse of antifungal agents. However, azole resistance in A. fumigatus and Aspergillus flavus has also emerged in India. 23, 24 Consequently, a stewardship programme is urgently needed to preserve the few antifungal drugs currently available and to use them more effectively in those patients who would benefit the most. The meeting focused on constructing a national plan (Table 1) .
Two key areas were identified:
(i) Improving diagnosis by culture with species identification and susceptibility testing and making access to biomarkers (galactomannan, b-D-glucan and PCR diagnosis) affordable for early detection of IFI. Other diagnostic tools, such as CT/MRI, should be made available at tertiary care centres. (ii) Optimizing the appropriate use of antifungals for proven and probable cases of fungal infections.
Consensus opinions
The following consensus opinions were reached:
A. Is antifungal stewardship needed?
The group agreed that active antifungal stewardship is necessary. Our experience with antibiotic stewardship has taught us that we were late in initiating antibiotic stewardship. There is therefore an opportunity to start early for antifungal stewardship now, before the resistance problems seen with antibiotics also occur with antifungals.
B. Should antifungal stewardship be a part of the AMSP?
The common sentiment was that it would be prudent to place antifungal stewardship under the broad umbrella of antimicrobial stewardship programmes, to maximize support from the Ministry of Health and Family Welfare of the Government of India. However, it was also felt that there might be a risk that the focus would mainly be on antibacterial agents as their use is more widespread and more is known and understood about their pharmacokinetics and pharmacodynamics. However, the relatively high cost and toxicity of antifungals and the specific challenges in managing fungal diseases justify a separate focus on antifungal stewardship. Yes, but antifungal stewardship should be separately addressed, though under the broad umbrella of the AMSP. However, it needs to be distinctly recognized as a separate entity. 3 Should antifungal use be monitored? (Patchy data are available across the country.)
Antifungal use data need to be collected along with the number of patients treated, to determine the baseline of antifungal use as DDD/1000 days. In resource-constrained settings, at least point prevalence studies need be done to obtain the baseline data. 4 Does local epidemiology data for IFI need to be collected?
Local epidemiology data for IFIs, including patient characteristics, spectrum of organisms and antifungal susceptibility with continuous surveillance, are necessary to develop management guidelines and choice of antifungal agents. 5 Should an antifungal policy be documented? If so, who should be making it?
An antifungal stewardship Task Force should be instituted consisting of physicians/infectious disease physicians, undergraduate (UGs) and postgraduates (PGs) from other specialties, clinical microbiologists, pharmacists and administrators, to formulate an antifungal policy. 6 What are the ways in which antifungal stewardship can be continually improved?
Regular education programmes at both UG and PG levels of training. The syllabus needs to be reoriented. Further initiate CME and workshops. A consensus document should be created, spelling out a common minimum level of diagnosis and standard diagnostic, prophylaxis and treatment algorithms. 7 How should the antifungal policy be implemented?
The antifungal stewardship Task Force should hold regular audits, analyse results and ensure corrective and preventive actions. 8 Should the antifungal policy be reviewed?
The Task Force should review the antifungal policy periodically (at least yearly) and update it as required. 9 Should formulation of national guidelines be explored?
A year after implementation of antifungal stewardship programmes at various institutes, the collective data could be analysed and consensus guidelines be formulated and put before the Government of India for implementation. Lessons learned and further ways forward can subsequently be addressed. CME, continuing medical education.
Review
Hence, it was concluded that while remaining as a part of the AMSP, antifungal stewardship should remain a separate entity, recognized as distinct from antibiotic stewardship.
C. Formulation and implementation of an effective antifungal stewardship programme
The following steps were outlined for step-by-step implementation countrywide
C.1. Monitoring antifungal use
There are few accurate data with regard to the quantity of antifungal drugs used in India. At Sir Ganga Ram Hospital, a tertiary care centre at New Delhi, India, the annual usage of antifungal drugs between 2000 and 2008 increased significantly from 0.627 to 8.77 prescribed daily doses (PDD)/1000 patient days. 15 These differ from DDD as per the WHO/ATC definition, which defines lower doses for amphotericin B and fluconazole (35 and 200 mg, respectively). 25 Fluconazole was the most frequently prescribed drug and there was a statistically significant correlation between yearly fluconazole use and the increase in isolation of Candida spp. other than C. albicans. 15 Regular auditing of the total amount of antifungal use, cost and toxicity is also important. The consensus was that data on antifungal use needs to be collected together with the number of patients treated to establish the baseline of antifungal use as DDD or PDD/1000 patient days or occupied bed days before starting any antifungal stewardship programme. Continuous data collection over a period of time is resource intensive, and it was therefore recommended that participating centres should obtain antifungal use data from point-prevalence studies. For appropriate dosing of azoles like voriconazole, it is desirable that TDM is recommended to users so that the pharmacokinetics/pharmacodynamics necessary to result in eradication of the fungal disease is achieved.
C.2. Local epidemiology data
Basic minimum standard criteria for the methods used to diagnose IFIs and identification with AST of fungal isolates are required. However, initially the local epidemiology data should be collected from each centre, specifying the methods used.
There is a pertinent need to standardize AST methodology across the country. The broth dilution method for AST is considered the gold standard but is not suitable for every laboratory, especially where automated systems with quality control are preferred. Many centres in India do not use standard criteria to interpret susceptibility test results, so accurate resistance rates are lacking. Until standardization of the automated system is achieved, a laboratory using any other method than microbroth dilution may provide only susceptible reports for any isolate. However, when an isolate is found resistant by an automated system, its resistance should be confirmed by microbroth dilution. It needs to be recognized that clinical breakpoints of various antifungals are available for some Candida spp. (C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, C. krusei and C. guillermondii) and none for the moulds. This makes interpretation for some moulds and Candida spp. other than C. albicans spp. very difficult. Finally, internal quality control and enrolment in national external quality control programmes is recommended to ensure reliable and robust results.
C.3. Antifungal policy at the national level
There are few new drugs in development and resistance to available drugs is increasing. Therefore, it is necessary to ensure that antifungals are used rationally and optimally as per a policy to outline appropriate antifungal use. The success of any effective antimicrobial stewardship programme depends upon active participation of all stakeholders. An antifungal stewardship task force needs to be instituted, consisting of physicians from various specialties, including infectious diseases, clinical microbiology, pharmacy and hospital administration, who would be actively involved in formulating an antifungal policy. Since 'one size does not fit all', the policy must be tailored for each region and institute based on their own epidemiological data and patient population and the prevalence of disease.
C.4. Continual improvement
Regular education programmes across the country should be held to train the trainers using online learning tools, in addition to workshops and presentations. Various agencies and societies should be encouraged to undertake these activities. A consensus document defining minimum levels of diagnostic criteria should also be developed and diagnostic, prophylaxis and treatment algorithms should be formulated. Guidelines for de-escalation, switching from intravenous to oral administration and stopping therapy should also be specified.
C.5. Implementation of antifungal policy (audits)
The consensus was that the antifungal stewardship task force at each institute would be responsible for ensuring the implementation of the antifungal policy in a similar fashion to that established by the existing AMSP. Various methods, including restrictions in the antifungal formulary and using antifungal prescription stamps, could be employed. Such stamps contain fields such as when started, reasons for starting, dose and duration. The treating physician needs to complete these details so that antifungal prescribing can be audited. The task force would hold regular audits, analyse the results and, in case of irregularities, endeavour to identify the reasons for these and seek corrective remedies as well as measures to prevent the misuse of antifungals.
C.6. Review of antifungal policy
Daily coordination between clinicians, including specialists in infectious diseases and clinical microbiologists (mycologists), is essential to manage individual patients with fungal infections. For an antifungal stewardship programme to succeed it will require the task force to review the antifungal policy periodically (at least yearly, as with antibiotic policies) in the context of the local epidemiology.
C.7. Formulation of national guidelines AMSP can take advantage of existing antimicrobial stewardship programmes as the principles are essentially the same and should be recognized and formulated by the Ministry of Health and Family Welfare of the Government of India and ICMR while retaining its distinct entity. After a year of implementation of antifungal stewardship programmes at various institutes, the data from all centres Review JAC should be analysed and a consensus guideline be formulated which can be put before the government for implementation.
